{"id":"anlotinib-combined-with-benmelstobart","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Immune-related adverse events (pneumonitis, hepatitis)"},{"rate":null,"effect":"Hand-foot skin reaction"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Anlotinib inhibits multiple receptor tyrosine kinases (VEGFR, FGFR, PDGFR, c-Kit) to suppress tumor neovascularization and growth. Benmelstobart blocks the PD-L1/PD-1 checkpoint interaction, releasing T-cell inhibition and promoting anti-tumor immunity. The combination leverages both anti-angiogenic and immunotherapeutic mechanisms.","oneSentence":"Anlotinib is a multi-targeted tyrosine kinase inhibitor combined with benmelstobart (an anti-PD-L1 monoclonal antibody) to block tumor angiogenesis and enhance anti-tumor immune response.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:01:46.055Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced or metastatic non-small cell lung cancer (Phase 3 trial indication)"}]},"trialDetails":[{"nctId":"NCT07489300","phase":"PHASE2","title":"Benmelstobart in Combination With Anlotinib and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Epithelial OvariaN, Fallopian Tube, or Primary Peritoneal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2026-03-30","conditions":"Ovarian Cancer, Fallopian Tube Cancers, Primary Peritoneal Cancer","enrollment":40},{"nctId":"NCT06897579","phase":"PHASE2","title":"Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2025-04-07","conditions":"Extensive Stage Small Cell Lung Cancer","enrollment":134},{"nctId":"NCT07446335","phase":"PHASE3","title":"A Phase III Study of First-line Anlotinib Combined With Benmelstobart in Patients With Advanced Esophageal Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2026-04","conditions":"Advanced Esophageal Squamous Cell Carcinoma","enrollment":578},{"nctId":"NCT07193186","phase":"PHASE2","title":"Anlotinib and Benmelstobart in DTC","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-04-01","conditions":"Thyroid Cancer","enrollment":23},{"nctId":"NCT06662006","phase":"PHASE2","title":"Nal-IRI/5-FU/LV Chemotherapy Combined With PD-L1 Inhibitor and Multi-target Anti-angiogenic Small Molecule±SBRT as Second-line Therapy in Metastatic Pancreatic Cancer Patients","status":"RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2024-03-01","conditions":"Advanced Metastatic Pancreatic Cancer","enrollment":56},{"nctId":"NCT07294261","phase":"PHASE2","title":"Garsorasib In KRAS G12C Mutant Locally Advanced and Metastatic NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-12-23","conditions":"Local Advanced or Metastatic NSCLC","enrollment":69},{"nctId":"NCT06874933","phase":"PHASE2","title":"Neoadjuvant Chemotherapy in Combination With Anlotinib and Benmelstobart for HR+/HER2- Breast Cancer (NEOTORCH-BREAST03)","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2025-05-04","conditions":"HR+/HER2- Breast Cancer","enrollment":35},{"nctId":"NCT06848439","phase":"PHASE2","title":"Benmelstobart-Anlotinib-Chemo for Neoadjuvant Oral Cancer","status":"NOT_YET_RECRUITING","sponsor":"Jiangsu Cancer Institute & Hospital","startDate":"2025-06-15","conditions":"Mouth Neoplasms, Neoadjuvant Therapy, Immunotherapy","enrollment":26},{"nctId":"NCT06978153","phase":"PHASE2","title":"This is a Two-cohort, Exploratory Clinical Study Assessing the Activity of Benmelstobart Combined With Chemotherapy With or Without Anlotinib in Resectable Limited-Stage Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tang-Du Hospital","startDate":"2025-05-20","conditions":"Limited Stage Small Cell Lung Cancer","enrollment":66},{"nctId":"NCT06429397","phase":"PHASE2","title":"Anlotinib Combined With Benmelstobart for Advanced Pheochromocytoma","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-05-01","conditions":"Pheochromocytoma","enrollment":22},{"nctId":"NCT06931145","phase":"PHASE4","title":"Benmelstobart, Anlotinib and Chemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2025-04-15","conditions":"Extensive-stage Small Cell Lung Cancer","enrollment":50},{"nctId":"NCT06851169","phase":"PHASE2","title":"This is a Two-cohort, Exploratory Clinical Study Assessing the Activity of Benmelstobart Alone or Combined with Anlotinib Administered Prior to Surgery in Terms of Pathological Complete Response","status":"NOT_YET_RECRUITING","sponsor":"Tang-Du Hospital","startDate":"2025-04-01","conditions":"Non Small Cell Lung Cancer","enrollment":58},{"nctId":"NCT06699498","phase":"PHASE2","title":"Neoadjuvant Therapy of Targeted Immunotherapy Combined With Chemotherapy for Locally Advanced HNSCC","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-12-03","conditions":"Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy, PD-L1","enrollment":45}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":24,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"anlotinib combined with benmelstobart","genericName":"anlotinib combined with benmelstobart","companyName":"The First Affiliated Hospital of Zhengzhou University","companyId":"the-first-affiliated-hospital-of-zhengzhou-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Anlotinib is a multi-targeted tyrosine kinase inhibitor combined with benmelstobart (an anti-PD-L1 monoclonal antibody) to block tumor angiogenesis and enhance anti-tumor immune response. Used for Advanced or metastatic non-small cell lung cancer (Phase 3 trial indication).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}